Медикаментозна корекція метаболічних та імунологічних порушень, інтенсивності системного запалення та ендотеліальної дисфункції у пацієнтів з поєднаним перебігом серцево-судинних та бронхообструктивних захворювань, ураженням опорно-рухового апарату та хронічними дерматозами . № держреєстрації 0120U101550. Термін виконання 2020-2024 рр.

Increasing the effectiveness of treatment of patients with a combined course of coronary heart disease and COPD, damage to the musculoskeletal system with accompanying poor ventricles. Determination of the nature of changes in the functional activity of the pituitary-thyroid system and the state of the microbiota of the colon cavity depending on the severity of the clinical course of dermatosis in patients with acne, living in a region with natural iodine deficiency, and in patients with rosacea - the nature of changes in indicators of oxidative modification of proteins will allow to develop recommendations for improving diagnostic and treatment tactics for this group of patients. determining in patients with lichen planus and rosacea the nature of changes in indicators of pro-oxidant-antioxidant homeostasis and pro-inflammatory and anti-inflammatory cytokines depending on the severity of the clinical course of these dermatoses, and in patients with allergic dermatoses with concomitant diffuse lesions of the liver of non-viral genesis, biochemical indicators of blood will allow the development of pathogenetically based recommendations for improvement of diagnostic and treatment tactics for such patients. Methods of complex treatment of patients with psoriasis and acne vulgaris with differentiated use of immunotropic drugs and probiotics, a method of complex treatment of patients with rosacea with the use of antioxidant and anti-inflammatory agents, as well as a method of complex treatment of patients with lichen planus with the use of a polyenzyme drug and low-intensity laser therapy have been developed. which allows to increase the efficiency of treatment of such patients.

Reduction of financial costs for the treatment of patients with a combined course of coronary heart disease and COPD, damage to the musculoskeletal system, chronic dermatoses with accompanying comorbid conditions by increasing the effectiveness of complex treatment and reducing the length of stay in a hospital. Reduction of financial costs for the treatment of patients with psoriasis, chronic pyoderma, eczema and lichen planus due to shortening the terms of their treatment and reducing the frequency of relapses of chronic dermatoses in them by increasing the effectiveness of their complex therapy due to the introduction into treatment of developed therapy schemes taking into account indicators of immune system, prooxidant-antioxidant homeostasis and colon microbiota of such patients.

Services are provided to patients with the above-mentioned pathological conditions

Open, free